Vandortuzumab vedotin
Vandortuzumab vedotin (INN; development code RG7450) is a humanized monoclonal antibody designed for the treatment of cancer.[1][2]
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Humanized (from mouse) |
Target | STEAP1 |
Clinical data | |
Other names | RG7450 |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C6608H10168N1756O2076S44 |
Molar mass | 148838.89 g·mol−1 |
This drug was developed by Genentech/Roche. Development was discontinued in 2017.[3]
References
- Statement On A Nonproprietary Name Adopted By The USAN Council - Vandortuzumab Vedotin, American Medical Association.
- World Health Organization (2014). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 112" (PDF). WHO Drug Information. 28 (4).
- "Vandortuzumab vedotin". AdisInsight. Springer Nature Switzerland AG.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.